CMOS Study

Cannabinoid Medicine Observational Study (CMOS)

Medicinal cannabis became legal to prescribe in Australia for medicinal purposes in late 2016. However, since this access change there have been limited efforts to systematically collect data on prescribing patterns, patient outcomes and safety related to medicinal cannabis prescribing. We are now at a stage where there are large numbers of approvals for unregistered medicinal cannabis products in Australia, yet no supporting data around how this prescribing has affected treatment outcomes. A number of directed clinical studies are underway across Australia using medicinal cannabis products, however these are not capturing data on a large scale, across different product types, different geographies, different clinician types and different indication groups.

CMOS, the Cannabinoid Medicine Observational Study, aims to fill this gap within the Australian research community and collect important real-world evidence on Australian medicinal cannabis prescribing and its outcomes. As Australia’s largest medicinal cannabis observational study, CMOS aims to recruit 20,000 patients within a 5 year period which will create a dataset that is more representative of the broader Australian community. 

How it works - Cmos Study

CMOS aims to assess the prescribing patterns of medicinal cannabis from Australian clinicians including GPs and specialists from all Australian states.  

CMOS will collect data about the safety and efficacy of medicinal cannabis products for a range of clinical conditions including but not limited to: 

  • Chronic pain conditions (e.g. fibromyalgia)
  • Mental health conditions (e.g. PTSD) 
  • Neurological conditions (e.g. epilepsy) 
  • Inflammatory conditions (e.g. arthritis, IBD)

Data will be collected from both patients and their prescribing clinicians throughout their treatment (maximum 12 month period of follow up). The questionnaires included in the study focus on side effects, patient satisfaction, medication adherence, health-related quality of life and changes to other concomitant medications.

For more specific study information please select:

I'm a

Medicinal cannabis trails Doctos & Patients ACR

I'm a